Reduction of breast tumor drug resistance by 2,3,5,4′-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect

Yao-Yuan Chang1, Hung-Jun Lin1, Ling-Chi Hsiao1, Yu-Feng Lin2, Chih-Sheng Chang3*, Der-Zen Liu1,4*

1 Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan, 2 Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 3 Department of Horticulture Science, National Chiayi University, Chiayi City, Taiwan, 4 Medical and Pharmaceutical Industry Technology and Development Center, New Taipei, Taiwan

* tonyliu@tmu.edu.tw (DZL); changcs200@yahoo.com.tw (CSC)

Abstract

Chemotherapy drugs have limited efficacy in breast cancer due to multidrug resistance generated by cancer cells against anticancer drugs. In this study, we developed a novel derivative, 2,3,5,4′-tetrahydroxystilbene (TG1) by modifying 2,3,5,4′-tetrahydroxystilbene-2-O-beta-D-glucoside (THSG). In-vivo zebrafish embryo tests revealed that TG1 showed low toxicity. The equitoxic combination of DOX or DTX with TG1 in MCF-7/Adr reduced the IC50 of DOX or DTX, and the combination index (CI) showed strong synergistic effects in the 1:3 molar ratio of DTX: TG1 and 1:5 molar ratio of DOX: TG1. Moreover, fluorescence images confirmed the cellular uptake of DOX when combined with TG1 in MCF-7/Adr. Western blotting analysis indicated downregulation of p-glycoprotein (P-gp) after MCF-7/Adr treated with TG1. In conclusion, the combined therapy of DTX or DOX and TG1 increases drug efficacy via suppressing the p-glycoprotein efflux pump. These results suggest that TG1 may have potential use for breast cancer patients, especially those with multidrug resistance.

Introduction

Breast cancer is one of the most common cancers in the world, and has the highest mortality rate among all cancers in women [1]. Previous reports have shown that approximately 12.3% of women in the US will be diagnosed with breast cancer during their lifetime, and it was predicted that it will reach up to 22 million new cases worldwide in a decade [2–4]. Thus, treating breast cancer efficiently is always an important issue for researchers. Surgery, chemotherapy and radiation therapy are the major treatments for breast cancer patients currently. Chemotherapy is useful for treating various stages of breast cancer, and is used preoperatively to shrink the tumor or postoperatively to eliminate residual tumor cells after surgical removal [5, 6]. Many chemotherapy drugs are used for breast cancer treatment, including doxorubicin (DOX), paclitaxel, docetaxel (DTX) and others. However, anti-tumor efficacy is often limited by the multidrug resistance (MDR), ultimately resulting in the failure of chemotherapy [7, 8]. Thus, MDR has become a significant problem for breast cancer treatment.
MDR has affected more than 80% of breast cancer patients after chemotherapy [9, 10]. Upregulation of ATP-binding cassette transporters (ABC transporters) on breast cancer cells is the major mechanism of MDR. ABC transporters, including p-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and breast cancer resistance protein (BCRP) are cell membrane efflux pumps, and their role is to modulate intracellular drug concentrations [9, 11, 12]. However, overexpression of ABC transporters pumps anticancer drugs out of cancer cells from intracellular to extracellular, resulting in losing the anti-cancer ability and failure of chemotherapy.

In order to overcome the MDR effect, a chemosensitizer must be developed to inhibit overexpression of ABC transporters. Different inhibitors, such as ribozymes, siRNA and antisense oligonucleotides have been validated previously to successfully reduce the expression of ABC transporters [13–15]. However, promising chemosensitizers are still lacking in clinical treatment because of previously identified undesirable drawbacks such as low potency and high toxicity [16, 17]. Recently, researchers are focusing on natural plants extraction and subsequent structural modification to develop chemosensitizers with versatile applications and low toxicities [18, 19]. 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (THSG), which is extracted from Agave sisalana, Polygonum multiflorum and Fallopia japonica. The aim of this study was to demonstrate the synergistic effects of a novel chemosensitizer, TG1, combined with an anti-cancer drug to overcome multidrug resistance in breast cancer treatment.

Materials and methods

Production of TG1

THSG was extracted from Polygonum multiflorum as described in a previous study [20]. Briefly, Polygonum multiflorum leaves, roots and rhizomes were pulverized and soaked in 60% methanol for one day. After filtration, the residues were twice extracted with 60% methanol, and then concentrated with a rotary evaporator. The aqueous solution was chromatographed on a Diaion HP-20 column (30cm id x 90cm) eluted with H2O, 50% MeOH and 100% MeOH. The 50% MeOH eluate was chromatographed over a RH-18 column (10cm id x 60cm) eluted with 0.05% trifluoroacetic acid-CH3CN (82:18) to produce THSG. To form a THSG solution (2.06 g, 5.62 mmol) in EtOH (50 mL) was added 1.0 N HCl (70 mL), refluxed for 14 hours. The mixture was cooled to room temperature and EtOH was removed under reduced pressure. The residue was extracted with ether, and the organic layers were collected, dried over MgSO4, concentrated under reduced pressure, and purified by column chromatography (silica gel; DCM/MeOH = 16/1) to produce TG1 as a brown solid. After flash column purification, TG1 was dissolved in MeOH and recrystallized with CHCl3 to produce brown-green powder (400 mg, 32% yield). The compound structure of TG1 was examined its 1H and 13C using nuclear magnetic resonance (NMR), (Bruker Avance DRX 500MHz, Bruker Corp., Billerica, MA, USA).

Cells

Two different types of human breast cancer cell lines were used. The first was MCF-7 cells, a model human breast cancer cell line, which was purchased from Bioresource Collection and Research Center (BCRC, Taiwan), and the second was MCF-7/Adr cells, a human breast cancer multidrug resistant (MDR) cell line, which was kindly provided by Professor Jun-Jen Liu (Taipei Medical University, Taiwan). In addition, L929 human fibroblast cell lines were purchased from BCRC, Taiwan, for in-vitro toxicity examination.

MCF-7 cells were cultured in Minimum Essential Medium (Gibco; Invitrogen, Waltham, MA, USA) containing L-Glutamine, 2.2g/L sodium bicarbonate, 0.1mM non-essential amino acids solution, 1.0 mM sodium pyruvate, 10% fetal bovine serum (FBS), and 1% penicillin/
streptomycin (PS). MCF-7/Adr cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco) containing 10% FBS and 1% PS. L929 cells were cultured in RPMI containing 10% FBS and 1% PS. All cell lines were maintained in a humidified atmosphere with 5% CO₂ in a 37°C incubator and the culture medium was replaced every 2–3 days.

**Cell viability examination**

Cell viability was analyzed by Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma- Aldrich, St. Louis, MO, USA). The cells were first placed in 48-well plates (Nunc) at a density of 1x10⁴ cells/well. After incubation for cells attached in the 48-well plates, each well would be placed into different drug conditions for 24 hours. Since the drugs were insoluble in water, they were dissolved in 0.1% dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO, USA). Then, each well would be substituted by the culture medium containing 10% MTT solution, which were made up in 5 mg/ml solution operated in dark place. After incubation for 4 hours, the supernatants were removed and 500 μl DMSO was added into each well to solubilize the formazan crystals. Finally, they were transferred into 96-well plates and then the absorption wavelength was measured at 570 nm by ELISA reader (Sunrise). The IC₅₀ value was calculated by the GraphPad Prism programme.

**Zebrafish embryo-toxicity test**

Zebrafish (Danio rerio) were maintained at 28°C under continuous flow of air and with automatic control of a 14-hour light/ 10-hour dark cycle. All zebrafish experiments were conducted under the approval of the institutional animal care and use committee (IACUC). Zebrafish embryo-toxicity test was performed according to guidelines of the Organization for Economic Co-operation and Development. The day prior to fertilization, male and female fish were left in mating tanks overnight. The next morning, the embryos were collected and transferred to a dish with E3 solution (5mM NaCl, 0.17mM KCl, 0.33mM CaCl₂ and 0.33mM MgSO₄, pH 7.0) and incubated at 28°C for 6 hours. Thirty-five embryos were produced and each of the 35 embryos were incubated and exposed to the range of concentrations between 12.5 μM and 1600 μM of TG1 for 1 day and 2 days. The number of dead embryos/fish and normal fish were recorded.

**Assessment of drug combination synergism and combination index.** In 1984, Chou and Talalay published a concept collaboratively addressing the term “Combination Index (CI),” explaining that the value quantitatively symbolized and analyzed drug potencies [21, 22]. Since the term was introduced, CI has been extensively used in scientific articles internationally. CI more than 1 means antagonism of the drugs; CI equal to 1 points to additive effects of the drugs; CI less than 1 implies synergistic effect of the drugs.

The mathematical formula for CI is as follows:

\[
\begin{align*}
d_1 &= \left( \frac{a}{a+b} \right) \text{ED}_{50(1)} \\
d_2 &= \left( \frac{a}{a+b} \right) \text{ED}_{50(2)} \\
\text{CI} &= \frac{d_1}{\text{ED}_{50(1)}} + \frac{d_2}{\text{ED}_{50(2)}} = \left\{ \frac{a}{(a+b)\text{ED}_{50(1)}} + \frac{b}{(a+b)\text{ED}_{50(2)}} \right\} \text{ED}_{50c}
\end{align*}
\]
First, “d1” and “d2” signify doses of the drugs individually; second, “a” and “b” represent the drug ratios, respectively; third, “ED_{50(1)}” and “ED_{50(2)}” indicate the median effect doses of the drugs, respectively, while “ED_{50c}” expresses the median effect dose of the drugs combined.

The principle and formula of CI can be applied to analysis and discussion of multiple drug potencies for cancer treatment. Therefore, this study aimed to calculate CIs to evaluate whether anticancer drugs and chemosensitizers exhibited synergistic effects or not.

**Fluorescence examination of doxorubicin cellular uptake.** Fluorescence images are used to analyze and investigate the effects of the multidrug resistance drug efflux pump in vitro. Because doxorubicin has a fluorescence signal, this property was used to detect and observe the images.

The breast cancer cells, MCF-7 and the multidrug resistance breast cancer cells, MCF-7/Adr were first placed in 48-well plates (Nunc) at a density of 2x10^4 cells/well. After incubation of cells in the 48-well plates, each well was placed into different drug conditions (DOX, DOX+TG1 = 1:5) for 24 hours. Subsequently, the medium was removed and cells were rinsed 3 times with PBS. To fix the cells, 200μl 4% paraformaldehyde was added to each well for 15~20 minutes at room temperature. Then, the solution was removed and washed with PBS 3 times (4 minutes each). Finally, an excitation wavelength at 488 nm and emission wavelength at 520 nm were detected by inverted fluorescence microscope (Leica).

**Drug resistance associated proteins expression analysis**

In order to investigate the multidrug resistance pathways between the anticancer drugs and the chemosensitizers, analysis of specific protein expression was conducted using western blotting.

Briefly, MCF7 or MCF7/Adr cells of the control group and drug of the experimental group (DOX, TG1 or DOX+TG1) were incubated for 72 hours. The cells were harvested with lysis solution (cell lysis buffer: Phosphatase Inhibitor Mix II: Protease Inhibitor Cocktail = 100:1:1) for 30 minutes at 4˚C. The total protein levels were determined with a BCA assay (Bio-RAD, CA, USA) depends on the Bradford method. Equal amounts of protein (20μg) were separated with 8%-15% SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membrane was blocked with 5% BSA in PBST for 1 hour. Then, the primary antibodies included P-gp (1:500, mAb; Merck, MA, USA), MRP1(1:500, mAb; Merck, MA, USA), BCRP (1:500, mAb; Merck, MA, USA) or β-actin (1:1000, polyclonal Ab; Cambridge, UK) were incubated in 1% BSA dilution at 4˚C overnight. On the next day, the membrane was washed for 1 hour with PBST. Then, HRP-conjugated secondary antibody solution in PBST dilution (1:1000) was incubated for 2 hours at room temperature.

To detect chemiluminescent signal, chemiluminescent substrate of 1:1(v/v) was added to the membrane. It was captured by BioSpectrum® 810 Imaging System™ (UVP). For image analysis, the band intensity of the target proteins was gained by software (N = 3 for each group).

**Statistical analysis**

Data are reported as mean and standard deviation. The significance of the data was analyzed by Mann-Whitney U test between the control group and the experimental groups. Statistical testing was performed using GraphPad Prism (GraphPad Software, Inc., San Diego, CA), and a p-value < 0.01 was considered statistically significant.

**Results**

**TG1 compound structure**

The compound structure of TG1 is shown in Fig 1, and was identified by NMR. TG1 $^1$H NMR (200 MHz, MeOD) δ 7.31, 6.72 (dt, J = 8.5, 2.9, 1.8 Hz; J = 8.7, 2.8, 2.0 Hz 2H; 2H, H-2', H-6',
H-3', H-5'), 7.21, 6.90 (d, J = 16.5 Hz; J = 16.4 Hz, 1H; 1H, H-7, H-8), 6.45, 6.20 ppm (d, J = 2.7 Hz; J = 2.7 Hz, 1H; 1H, H-3, H-5);

\[ \delta \]

\[ \begin{align*} 
13C \text{ NMR (50 MHz, MeOD}} \delta & \text{ 157.1, 150.3, 146.5, 136.4(C2, C4, C6, C4'), 130.1, 126.0(C1, C1'), 128.1, 120.7(C7, C8), 127.7, 115.4(C2', C3', C4', C5'), 102.1, 101.9 \text{ ppm (C3, C5).} 
\end{align*} \]

Toxicity of TG1

The zebrafish animal system is thought to be a cost-effective tool for anticancer drug development [23, 24]. To evaluate the primary in-vivo toxicity of TG1, zebrafish embryos were exposed to various drug concentration of TG1 (range of concentrations between 12.5 \( \mu \text{M} \) and 1600 \( \mu \text{M} \)) at time points 24 and 48 hours post fertilization (hpf) (Fig 2A–2C). The survival rates were not significantly affected under 1600 \( \mu \text{M} \) of TG1 at 24 hpf. We found that zebrafish embryos exhibited a significantly decreased survival rate only when they were exposed to high concentration of TG1 (1600 \( \mu \text{M} \)) at 48 hpf.

L929 human fibroblast cells were used to analyze the cytotoxicity of TG1 invitro. Even if the concentration of TG1 was over 100 \( \mu \text{M} \) (Fig 2D), the L929 cells still maintained high cell viability, indicating the low toxicity of TG1 for fibroblast cells.

These results suggest no obvious in-vitro cellular toxicity or in-vivo developmental toxicity for TG1, suggesting its potential for further clinical applications.

In-vitro antitumor effect of TG1

For the breast cancer cells viability test, MCF-7 cells were examined for TG1 cytotoxicity and that of clinical drugs, docetaxel and doxorubicin. IC\textsubscript{50} values of DTX and DOX were 1.43 \( \pm \) 0.09 \( \mu \text{M} \) and 0.96 \( \pm \) 0.08 \( \mu \text{M} \), respectively (Fig 3A), while IC\textsubscript{50} values of TG1 were 257.1 \( \pm \) 1.79 \( \mu \text{M} \) (Fig 4A), indicating slight influence on the growth of breast cancer cells.

MCF-7/Adr cells and human breast cancer MDR cells were also examined for cellular cytotoxicity of DTX, DOX and TG1. IC\textsubscript{50} values of DTX and DOX were 8.98 \( \pm \) 0.81 \( \mu \text{M} \) and 5.49 \( \pm \) 0.49 \( \mu \text{M} \), respectively (Fig 3B), which were higher than the IC\textsubscript{50} values of MCF-7,
indicating drug resistance effects of the breast cancer cells. IC_{50} of TG1 treated with MCF-7/Adr was 260.8 ± 1.79 μM (Fig 4B), which was similar to TG1 on MCF-7.

**Combination effect of TG1 and clinical drugs**

For evaluation of cell cytotoxicity efficiency of anticancer drugs combined with TG1 for drug-resistant MCF-7/Adr cells, MTT assay was tested using the molar ratio of 1:1, 1:2, 1:3, 1:5 and 1:10 (DTX or DOX: TG1) (Figs 5A and 6A). TG1 was shown to effectively enhance the anti-cancer ability regardless of the molar ratio. Based on cell viability results, the combination index (CI) was calculated to ascertain the drug potencies of clinical drugs combined with TG1. As the CI value was less than 1, the drug combination exhibited synergistic effects (Fig 5B). The CI value of 1:1 (DTX: TG1) was 0.86, indicating weak synergistic effects. However, strong synergistic effects were shown with the molar ratio 1:3, and the CI value was lower than 0.2. For DOX and TG1 combination treatment, molar ratio 1:5 had strong synergistic effects and the CI value was 0.18 (Fig 6B). Thus, the 1:5 molar ratio of drugs and TG1 combination appears to be the most effective formulation against drug resistant breast cancer cells, suggesting their potential for further clinical application.

**In vitro cellular uptake for breast cancer cells**

To visualize MDR effects, the fluorescence signal of DOX was evaluated to detect cellular uptake of breast cancer cells (Fig 7). In MCF-7 cells, both DOX treatment and DOX/TG1 treatment were found in breast cancer cells, however, distinct images were seen in MCF-7/Adr.
MCF-7/Adr images showed that the fluorescence signal of the DOX was found in the outer part of nucleus and cytoplasm because of the action of the drug efflux pump; however, the DOX fluorescence signal of DOX/TG1 treatment was detected in the cell nucleus, indicating good internalization by TG1.

Fig 3. Inhibition of DOX or DTX on proliferation of (A) MCF-7 and (B) MCF-7/Adr cells. The IC$_{50}$ values of DOX or DTX were calculated and showed on table. Data were shown by mean ± SD, n = 3.

https://doi.org/10.1371/journal.pone.0260533.g003

MCF-7/Adr images showed that the fluorescence signal of the DOX was found in the outer part of nucleus and cytoplasm because of the action of the drug efflux pump; however, the DOX fluorescence signal of DOX/TG1 treatment was detected in the cell nucleus, indicating good internalization by TG1.

Fig 4. Inhibition of TG1 on proliferation of (A) MCF-7 and (B) MCF-7/Adr cells. The IC$_{50}$ values of TG1 were calculated and showed on table. Data were shown by mean ± SD, n = 3.

https://doi.org/10.1371/journal.pone.0260533.g004
Presentation of MDR related transporters

Western blotting was used to assess multidrug resistance by ABC transporters, by analyzing the expression of different drug efflux pumps. Comparisons of the expression of P-gp, MRP1, and BCRP in MCF-7 and MCF-7/Adr are shown in Fig 8. P-gp expression in MCF-7/Adr was much higher than MCF-7, but the expression of MRP1 and BCRP in MCF-7/Adr was similar to MCF-7. However, when MCF-7 and MCF-7/Adr were treated with TG1 for 72 hours, P-gp expressions were also suppressed in both (Fig 8), with highly intense P-gp inhibitory effects in MCF-7/Adr. Nevertheless, neither MRP1 nor BCRP expression was affected after TG1 treatment.

To evaluate the chemosensitizing effects of TG1, cancer drugs were combined for treatment. After DOX treatment in MCF-7/Adr, P-gp expression was higher than the groups without any drug treatment. However, no increases were shown in MRP1 and BCRP expression after the treatment. Next, when DOX and TG1 were treated together in MCF-7 and MCF-7/Adr...
Adr, P-gp expression was suppressed in both, especially in MCF-7/Adr (Fig 9). These results indicate that TG1 may play an important role in inhibiting the P-gp drug efflux pump expression, which prevents anticancer drugs from being pumped out to the extracellular region.

**Discussion**

The present study attempted to find a safe and effective way to solve chemotherapy failure due to severe side effects of anticancer drugs and the difficulty of sustaining clinical treatment. In particular, chemotherapy drugs have limited efficacy in breast cancer due to multidrug resistance generated by cancer cells against anticancer drugs. In this study, the novel compound, TG1, showed low toxicity and potential application for breast cancer patients, especially those with multidrug resistance.

Many scientists have tried various means to ameliorate chemotherapy effects, including the use of non-toxic drug carriers or using new herbal compounds [25, 26]. In the present study, the properties of cytotoxicity, combination index, and drug efflux pump expression of TG1 were investigated. TG1 was derived from THSG deglucosylation, and it has a chemical
structure with multiple hydroxyl groups. Previous study indicated that hydrogen bonds were formed between the hydroxyl groups of inhibitors and the R site of drug efflux pump, P-gp [27]. Thus, the modification of THSG may have improved the reduction of drug efflux effect via P-gp.

Zebrafish are a model vertebrate that has been useful in human drug screening because humans and zebrafish have many of the same orthologous genes [28], and its advantages as a material for drug development are rapid development, high fecundity and relatively inexpensive [29]. Therefore, it is a beneficial model for drug safety assessment. Previous studies have revealed that the drug of the atracylodin induced the mortality with the LC$_{50}$ 52 μM [30]. However, zebrafish embryos exposed to TG1 under concentration of 800 μM showed a great in-vivo survival rate.

Based on results of previous studies, resveratrol acted as a fine chemosensitizer to support the anti-cancer efficacy when combined with clinical drugs, DOX or DTX [31–33]. The authors pointed out that the combination of resveratrol with DTX or DOX in the molar ratio of 1:15000 or 1:1 to 1:6 produced moderate synergistic effects (CI < 0.7~0.85) and slightly antagonistic (CI > 1), respectively. Xiong Guo et al. also showed the CI of DTX combined with resveratrol in the ratio of 2:1, 1:1, and 1:2 was 0.92, 0.64, and 1.2, which indicated that in the ratio of 1:2 had an antagonistic effect [25]. In the present study, the combination indexes had better synergistic effects than resveratrol. The combination treatment of anticancer drugs and
TG1 may have the highest effectiveness in the molar ratio of 1:3 (DTX: TG1, CI = 0.19) and 1:5 (DOX: TG1, CI = 0.18).

One of the important pathways was the drug efflux pumps located on the cell membrane, called ABC transporters [34]. Among these multiple transporters, P-gp was shown to play a vital role in developing resistance to anticancer drugs by overexpression in breast cancer cells [35–37]. Therefore, in the present study, two cell lines were used to compare the effects; MCF-7, and MDR cancer cells, MCF-7/Adr, which was a P-gp overexpressing derivative cells [38]. A better synergistic effect was shown in the present study than resveratrol according to the combination indexes. The combination treatment of anticancer drugs-DOX and TG1 appear to have the most effectiveness in the molar ratio of 1:5, indicating that the anticancer drugs can be reduced and maintained their effects at the same time.

In addition, TG1 also inhibits P-gp expression when the anticancer drugs were reacted against cancer cells, which demonstrated better effects than resveratrol [39]. Therefore, it would result in assisting anticancer drugs to exert the cytotoxicity via downregulating the drug efflux pump expression, especially performed on multidrug resistance cancer cells. Xue et al. determined metformin was an inhibitor rather than substrate of P-gp by bidirectional transport assay in MDR1-MDCK cells [40]. Resveratrol had a similar bi directional transport result with metformin [41]. Furthermore, many researches were investigated resveratrol as a P-gp inhibitor on cancer cells overexpressing P-gp [42–44]. Since TG1 has similar chemical structure with resveratrol, and the potential P-gp inhibitor could be predicted by structure [27].
TG1 might be a P-gp inhibitor to modulate DTX/DOX resistance effects, but it needs more investigation in the future.

**Conclusion**

The novel derivative TG1 exhibits no obvious in-vitro cellular toxicity or in-vivo developmental toxicity. The combination of anticancer drugs and TG1 promotes cytotoxicity against breast cancer cells because of its inhibitory effects on multidrug resistance, especially for p-glycoprotein drug efflux pump suppression. Therefore, this novel combinational therapy exhibits potential synergistic effects on treating breast cancer cells, especially those with multidrug resistance.

**Supporting information**

S1 Raw images. (PDF)

**Author Contributions**

**Conceptualization:** Yao-Yuan Chang, Hung-Jun Lin, Der-Zen Liu.

**Data curation:** Yao-Yuan Chang, Hung-Jun Lin.

**Formal analysis:** Hung-Jun Lin, Ling-Chi Hsiao.

**Funding acquisition:** Der-Zen Liu.

**Investigation:** Yu-Feng Lin.

**Methodology:** Yao-Yuan Chang, Hung-Jun Lin.

**Project administration:** Chih-Sheng Chang.

**Resources:** Yu-Feng Lin.

**Software:** Hung-Jun Lin, Ling-Chi Hsiao, Yu-Feng Lin.

**Supervision:** Chih-Sheng Chang, Der-Zen Liu.

**Validation:** Ling-Chi Hsiao.

**Visualization:** Ling-Chi Hsiao, Yu-Feng Lin.

**Writing – original draft:** Yao-Yuan Chang.

**Writing – review & editing:** Chih-Sheng Chang, Der-Zen Liu.

**References**

1. Hutchinson L. Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol. 2010; 7 (12):669–70. Epub 2010/12/01. https://doi.org/10.1038/nrclinonc.2010.192 PMID: 21116236.

2. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3):43–6. Epub 2016/05/12. https://doi.org/10.7314/apjcp.2016.17.s3.43 PMID: 27165206.

3. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64(1):52–62. Epub 2013/10/12. https://doi.org/10.3322/caac.21203 PMID: 24114568.

4. Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. 2021; 38(4):39. Epub 2021/03/16. https://doi.org/10.1007/s12032-021-01486-x PMID: 33721121.

5. Serenry M, Currie GL, Sena ES, Rammarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
6. Hayashi N, Takahashi Y, Matsuda N, Tsunoda H, Yoshida A, Suzuki K, et al. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype. Clin Breast Cancer. 2018; 18(2):e219–e29. Epub 2017/11/16. https://doi.org/10.1016/j.clbc.2017.09.013 PMID: 29138067.

7. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance. 2019; 2(2):141–60. https://doi.org/10.1016/j.cdr.2019.10.013 PMID: 34322663.

8. Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015; 15:71. Epub 2015/07/17. https://doi.org/10.1186/s12935-015-0221-1 PMID: 26180516; PubMed Central PMCID: PMC4502609.

9. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitratos P. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012; 38(7):890–903. Epub 2012/04/03. https://doi.org/10.1016/j.ctrv.2012.02.011 PMID: 22465195.

10. Galmarini CM, Galmarini FC. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs. 2003; 4(12):1416–21. PMID: 14763126.

11. Muley H, Fado R, Rodriguez-Rodriguez R, Casals N. Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol. 2020; 177:113959. Epub 2020/04/10. https://doi.org/10.1016/j.bcp.2020.113959 PMID: 32272110.

12. Ivanova L, Faeste CK, Solhaug A. Role of P-glycoprotein in deoxynivalenol-mediated in vitro toxicity. Toxicology letters. 2018; 284:21–8. Epub 2017/11/28. https://doi.org/10.1016/j.toxlet.2017.11.021 PMID: 29174985.

13. Kaspuziak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int J Oncol. 2007; 31(2):419–30. Epub 2007/07/06. PMID: 17611700.

14. Unato T. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance. Methods Mol Med. 2005; 106:215–33. Epub 2004/09/18. https://doi.org/10.1385/1-59259-854-4:215 PMID: 15375319.

15. Huesker M, Folmer Y, Schneider M, Fulda C, Blum HE, Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes. Hepatology. 2002; 36(4 Pt 1):874–84. Epub 2002/09/26. https://doi.org/10.1053/hep.2002.35619 PMID: 12297834.

16. Germann UA, Harding MW. Chemosensitizers to overcome and prevent multidrug resistance? J Natl Cancer Inst. 1995; 87(21):1573–5. Epub 1995/11/01. https://doi.org/10.1093/jnci/87.21.1573 PMID: 7563195.

17. Pradines B, Pages JM, Barbé J. Chemosensizers in drug transport mechanisms involved in protozoan resistance. Curr Drug Targets Infect Disord. 2005; 5(4):411–31. Epub 2006/03/16. https://doi.org/10.2174/156800500574912875 PMID: 16535862.

18. Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017; 36(1):19. Epub 2017/01/28. https://doi.org/10.1186/s13046-016-0487-8 PMID: 28126034; PubMed Central PMCID: PMC5270306.

19. Cho CJ, Yang CW, Wu CL, Ho JY, Yu CP, Wu ST, et al. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol Lett. 2019; 18(6):6869–76. Epub 2019/12/07. https://doi.org/10.3892/ol.2019.11023 PMID: 31807190; PubMed Central PMCID: PMC6876334.

20. Tsai PW, Lee YH, Chen LG, Lee CJ, Wang CC. In Vitro and In Vivo Anti-Osteoarthritis Effects of 2,3,5,4'-Tetrahydroxystilbene-2-O-beta-d-Glucoside from Polygonum Multiflorum. Molecules. 2018; 23(3). Epub 2018/03/08. https://doi.org/10.3390/molecules23030571 PMID: 29510478; PubMed Central PMCID: PMC6017566.

21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 24:27–55. Epub 1984/01/01. https://doi.org/10.1016/0065-2571(84)90007-4 PMID: 6382953.

22. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440–6. Epub 2010/01/14. https://doi.org/10.1158/0008-5472.CAN-09-1947 PMID: 20068163.

23. Li Y, Huang W, Huang S, Du J, Huang C. Screening of anti-cancer agent using zebrafish: Comparison with the MTT assay. Biochemical and Biophysical Research Communications. 2012; 422(1):85–90. https://doi.org/10.1016/j.bbrc.2012.04.110 PMID: 22560901.
24. Al-Thani HF, Shurbaj S, Yalcin HC. Zebrafish as a Model for Anticancer Nanomedicine Studies. Pharmaceuticals (Basel, Switzerland). 2021; 14(7). Epub 2021/07/03. https://doi.org/10.3390/ph14070625 PMID: 34203407; PubMed Central PMCID: PMC8308643.

25. Guo X, Zhao Z, Chen D, Qiao M, Wan F, Cun D, et al. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors. Asian J Pharm Sci. 2019; 14(1):78–85. Epub 2020/02/28. https://doi.org/10.1016/j.ajps.2018.03.002 PMID: 32104440; PubMed Central PMCID: PMC7032195.

26. Wang S, Meng Q, Xie Q, Zhang M. Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep. 2017; 15(3):1179–87. Epub 2017/01/19. https://doi.org/10.3892/mmr.2017.6111 PMID: 28098863; PubMed Central PMCID: PMC5367328.

27. Marques SM, Supolikova L, Molcanova L, Smjekal K, Bednar D, Staninova I. Screening of Natural Compounds as P-Glycoprotein Inhibitors against Multidrug Resistance. Biomedicines. 2021; 9(4). Epub 2021/04/04. https://doi.org/10.3390/biomedicines9040357 PMID: 33808505; PubMed Central PMCID: PMC8066904.

28. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Mufatto M, et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature. 2013; 496(7446):498–503. Epub 2013/04/19. https://doi.org/10.1038/nature12111 PMID: 23994743; PubMed Central PMCID: PMC3703927.

29. Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptschoss G, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A. 2009; 106(46):19485–90. Epub 2009/11/06. https://doi.org/10.1073/pnas.0909221106 PMID: 19887629; PubMed Central PMCID: PMC2790785.

30. Tshering G, Plengsuriyakarn T, Na-Bangchang K, Pimtong W. Embryotoxicity evaluation of atractylodin and beta-eudesmol using the zebrafish model. Comp Biochem Physiol C Toxicol Pharmacol. 2021; 239:108869. Epub 2020/08/18. https://doi.org/10.1016/j.cbpc.2020.108869 PMID: 32805444.

31. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011; 44(6):591–601. Epub 2011/10/21. https://doi.org/10.1111/j.1365-2184.2011.00783.x PMID: 22011009; PubMed Central PMCID: PMC6496784.

32. Lee SH, Lee YJ. Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells. Nutr Res Pract. 2021; 15(1):12–25. Epub 2021/02/06. https://doi.org/10.4162/nrp.2021.15.1.12 PMID: 35342789; PubMed Central PMCID: PMC7838474.

33. Schroeter A, Marko D. Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells. Molecules. 2014; 19(12):20054–72. Epub 2014/12/04. https://doi.org/10.3390/molecules191220054 PMID: 25470274; PubMed Central PMCID: PMC4622436.

34. Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 2016; 26:1–9. Epub 2016/05/18. https://doi.org/10.1016/j.drup.2016.03.001 PMID: 27180306.

35. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol. 2005; 32(6 Suppl 7):S9–15. Epub 2005/12/20. https://doi.org/10.1053/j.seminoncol.2005.09.009 PMID: 16360717.

36. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by mcri-298. Am J Pathol. 2012; 180(6):2490–503. Epub 2012/04/24. https://doi.org/10.1016/j.ajpath.2012.02.024 PMID: 22521303; PubMed Central PMCID: PMC3378910.

37. Chen T, Wang C, Liu Q, Meng Q, Sun H, Huo X, et al. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther. 2015; 16(1):106–14. Epub 2014/12/09. https://doi.org/10.4161/15384047.2014.987062 PMID: 25482933; PubMed Central PMCID: PMC4622436.

38. Pawlowska KM, Mucha J, Majchrzak K, Motyl T, Krol M. Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells. BMC Vet Res. 2013; 9:119. Epub 2013/06/19. https://doi.org/10.1186/1746-6148-9-119 PMID: 23773525; PubMed Central PMCID: PMC3698016.

39. Huang F, Wu XN, Chen J, Wang WX, Lu ZF. Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp Ther Med. 2014; 7(6):1611–6. Epub 2014/06/14. https://doi.org/10.3892/etm.2014.1662 PMID: 24926353; PubMed Central PMCID: PMC4043584.

40. Xue C, Wang C, Liu Q, Meng Q, Sun H, Huo X, et al. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Tumour Biol. 2016; 37(7):8587–97. Epub 2016/01/07. https://doi.org/10.1007/s13277-015-4478-8 PMID: 26733176.
41. Maier-Salomon A, Hagenaue B, Wirth M, Gabor F, Szekeres T, Jager W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res. 2006; 23(9):2107–15. Epub 2006/09/05. https://doi.org/10.1007/s11095-006-9060-z PMID: 16952002.

42. Choi JS, Choi BC, Kang KW. Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie. 2009; 64(1):49–52. Epub 2009/02/17. PMID: 19216231.

43. Wang Z, Zhang L, Ni Z, Sun J, Gao H, Cheng Z, et al. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-kappaB signaling and suppressing cAMP-responsive element transcriptional activity. Tumour Biol. 2015; 36(12):9499–510. Epub 2015/07/01. https://doi.org/10.1007/s13277-015-3636-3 PMID: 26124005.

44. Junco JJ, Mancha A, Malik G, Wei SJ, Kim DJ, Liang H, et al. Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid. Mol Cancer Res. 2013; 11(12):1521–9. Epub 2013/09/28. https://doi.org/10.1158/1541-7786.MCR-13-0237 PMID: 24072817; PubMed Central PMCID: PMC3869897.